HOME | PRODUCTS | OSTEOPOROSIS | Otosclerosis| BIOTINIDASE DEFICIENCY | RESEARCH | CONTACT US | PRIVACY POLICY

 

 

  • Fig. 2 Course of BMD at the lumbar spine during the three years of therapy (+ SD).

 

 

 

   

  • Table 4. Occurrence of new vertebral fractures during study

Group A

(MFP/Ca (interm.)

Group B

(MFP/Ca (cont.)

Group C

(Ca only)

After 1 year 4/4(10.5) 10/6 9/9(21.9)
After 2 years 4/4(11.4) 6/6(18.7 16/14(35.9)
After 3 years 1/1(3.1) 1/1(3.3) 11/11(32.4)
Within 3 years 9/8 17/12 36/30
Patient 3 years 105 100 114
New fractures per 100 patient years 8.6 17.0 31.6
  • Values are number of fractures/number of patients (%)

 

 

These statement on mericon-industries.com have not been evaluated by the Food and Drug Administration. The products and research on this website are not intended to diagnose, treat or cure or prevent disease.

 

Mericon Industries, Inc

All Rights Reserved 1998-2010